From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This study aims to investigate synaptic physiology and behavioral inhibition in patients with
NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by
lovastatin.
Structure: (1) Visit 1: Baseline assessment- participant's characterization, baseline outcome
measures and additional evaluations, (2) 3 consecutive days of physiologically probing
drug/placebo intake, (3) Visit 2: Outcome measures and additional evaluations in the day
after the last drug/placebo intake, (4) Washout period of 4 to 6 weeks, (5) 3 consecutive
days of drug/placebo intake, (6) Visit 3: Outcome measures and additional evaluations in the
day after the last placebo/drug intake.